---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-25-000017"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:39:58.742636+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics Q3 net loss $30.6M; completes Phase 2 LOTUS enrollment for AVTX-009

## Summary
- Completed enrollment in Phase 2 LOTUS trial (~250 adults) for AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.
- Cash and short-term investments $111.6M as of Sept 30, 2025; expected to fund operations into 2028.
- Net loss $30.6M in Q3 2025 vs net income $23.0M in Q3 2024; basic diluted EPS -$2.19.
- R&D expenses $13.6M (up $4.1M YoY) driven by LOTUS trial; G&A $5.6M (up $1.3M).
- Appointed Kevin Lind to Board; expanded leadership with new Chief Business Officer and SVP HR.

## SEC filing metadata
- accession: 0001534120-25-000017
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000017/0001534120-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000017/avtx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-25-000017
- JSON: https://secwatch.observer/filing/0001534120-25-000017.json
- Plain text: https://secwatch.observer/filing/0001534120-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.